Amgen Inc. (NASDAQ:AMGN)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for AMGN
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- joelsg1: $AMGN ATH-L
- Mikev200: @joelsg1 $AMGN nice. $XLV...Nice move without $LLY
- joelsg1: @Mikev200 $AMGN $XLV $LLY Holding this one for 15 years, since $47, with a little trading around. Best way to make big money is find and buy a great company and hold on, too hard to time the old in/out on any regular basis (though we all post about it here).
- woodman: @joelsg1 $AMGN $XLV $LLY - Congrats on that, Joel.
- joelsg1: $AMGN When big tech goes down, this goes up. High shelf pushing ATH, pays a $9 annual divi and has its own once a month weight loss drug in a fab pipeline. LT for me.
-
woodman: ...
I'm in LLY (not NVO) long term (and in $VKTX). Last time LLY had a significant drop I believe was after some $AMGN PR (AMGN's it turns out has its own tolerability issues). LLY dropped on the $AMGN PR. But then it went from $720s up to $960s. I str ... - Motorman: @woodman $LLY $NVO $VKTX $RHHBY $AMGN #Roche #OT Wow, a round the world, hope all is ok. I did the cologuard.
- billyzeke: @woodman $LLY $NVO $VKTX $RHHBY $AMGN #Roche That reminds me that I'm due for the colo..overdue actually. That prep...ugh! I got out of $LLY yesterday but am watching/wanting to get back in.
- woodman: @woodman $LLY $NVO $VKTX $RHHBY $AMGN #Roche - This captures most of my points: https://www.cnbc.com/video/2024/07/17/mizuhos-jared-holz-talks-roche-shares-surging-on-glp-1-data.html
- woodman: @Motorman $LLY $NVO $VKTX $RHHBY $AMGN #Roche #OT - The prep for a colonoscopy isn't the most fun you'll ever have, but the procedure is the gold standard for a deadly cancer that is avoidable if detected early through routine procedures. Plus, since I have to get an endoscopy now and again for some medical conditions that I have, I do the two birds with one stone deal.
- marklesparkle: @billyzeke $LLY $NVO $VKTX $RHHBY $AMGN #Roche @billy the good ole Bungholeascope
- billyzeke: @marklesparkle $LLY $NVO $VKTX $RHHBY $AMGN #Roche LOL When I call to schedule that's what I'm going to call it.
- Geewhiz: @woodman $VKTX $RHHBY $AMGN #Roche Oral dose chugging. Love it! Thanks so much.
-
woodman: ...
I'd note that $AMGN did the same thing a week or so ago when it provided data for its subcutaneous version. It didn't provide safety/tolerability data capable of assessment. VKTX seems to be the only one showing both its efficacy and safety/tolerabi ... - Bs7518: @woodman $VKTX $RHHBY $AMGN #Roche Great update I did add today
- woodman: @Bs7518 $VKTX $RHHBY $AMGN #Roche - 9 more catalysts in 2024! Many of these could be very important. (I said 8 in a recent post, but I forgot Phase 1b VK0214 (for X-ALD) data mid-yr. I haven't paid much attention to this one, nor does it seem anyone else has. I've not seen anything to suggest that it will be a real meaningful catalyst.)
- joelsg1: @woodman $VKTX $AMGN Gave up trials on its oral obesity pill, focusing on injectible.
- woodman: @joelsg1 $VKTX $AMGN - That's not new news.
- joelsg1: @woodman $VKTX $AMGN Confirmed in BofA conference yesterday.
- woodman: @joelsg1 $VKTX $AMGN - They said they were not going forward with oral on 5/2. https://www.cnbc.com/2024/05/02/amgen-scraps-experimental-weight-loss-pill-moves-forward-with-injection.html
- traderbren: $AMGN - still holding the May 310 puts which I bght on Friday. It was stretched outside the 3BB. Won't overstay my welcome as I don't want to be a pig. ;-)
- joelsg1: @traderbren $AMGN Legacy long for me from long ago with short upside covered calls to add juice to the 2.9% divi. Noticed this trades inverse to the Qs generally. Strong pipeline with an injectible once a month or longer weight-loss kicker they teased last week in Phase 3, though they terminated oral. Impressive base reversal but too quick. Looks like $300 round number key level.
-
StockMarketMentor: ...
Amgen ($AMGN) beat on Q1 earnings/revenues. The company also announced that it's continuing to develop its injectable obesity drug and pushing it into Phase 3 trials. So, there is going to be more competition for Novo Nordisk ($NVO) and Eli Lilly ... -
TraderGeekSam: ...
S&P 500 futures ($SPX) are up about 53 points after a weaker-than-expected non-farm payroll report, a well-received buyback from Apple ($AAPL), and the promise of another possible GLP drug from $AMGN. If we were to open here, the $SPX would test ... - debeers: A straight A Report Card? Easy- $AAPL $AMGN- $AMZN $ANF-Its wedding season folks! The wedding shop is NEW add back in the daddy-$NVDA now above the 50 A stock that almost always graduates with honors is $TOL no matter if the market is up or down $HD-over Lowes as builders made parking at Home Depot impossible Have yourselves a weekend folks!
- camaro69: $AMGN may have hit bottom yesterday. 2/6 earnings were good from what I can see and the stock has tanked. May be worth watching.
- Henry: @woodman $VKTX Cramer poo poo's it. $AMGN has one further along in phase 3 and the FDA tends to favor the first developer
- joelsg1: @Henry $VKTX $AMGN $AMGN is much less frequent injection, pill development too, and so far reasonably small side effects.
- woodman: @Henry $VKTX $AMGN - $AMGN is inferior in safety. 50% discontiue rate is huge! Huge percentage of nausea and vomiting, getting worse as the doseage increases. The problem seems to be that AMGN's MOA blocks receptors of the GIP hormone which apparently is causing more nausea and vomiting. Far less with $VKTX & $LLY.
- woodman: @woodman $VKTX $AMGN $LLY - I forgot, $AMGN's also showed 20% hypersensitivity and arrhythmias in two separate trials.
- woodman: $VKTX through $30, now through $31. Racing to Q1 data for oral obesity med (which isn't really my focus but certainly curious) and subcutaneous obesity (which is my focus). CEO was talking positively about a Phase 3 trial plan for subQ obesity med VK ...
- phgruver: @woodman $VKTX $LLY $NVO $PFE $AMGN You're loosing sight of the fact that this is primarily a treatment for Type-2 Diabetes. Currently, it has to be administered as a shot. If they can convert it to an effective pill, the market is huge! Weight loss is a bonus, but most Type-2 Diabetics are also overweight, so there's a lot of overlap. And, yes, you are correct, in order to bring it to market $VKTX will have to partner with, or sell out to a large pharma.
- joelsg1: @woodman $LLY $NVO $VKTX Agree, see $AMGN. And note $GPCR moving up, filled last gap, next fill at $49.
- woodman: @joelsg1 $LLY $NVO $VKTX $AMGN $GPCR - Nice with GPCR. That could be a winner for some of the obesity pie, too. Looks like a big gap fill potential to 56 and change.
- Zimzala: $AMGN Picked some up off the 50SMA.
- camaro69: $AMGN ATH
- joelsg1: @Motorman $GPCR Keep an eye on $AMGN, overcoming an FDA black box warning today on osteoporosis drug Prolea, which has dual mechanism obesity drugs in mid-stage development with hopefully fewer side effects and less frequent dosing. Lower volume breakout above high declining shelf into E 2/6. LT Long with short covered calls.
- Motorman: @joelsg1 $GPCR $AMGN thanks
- woodman: @joelsg1 $GPCR $AMGN - AMGN also quitely abandoned its Prolia/Denosumab Phase 3 trial for Osteogenesis Imperfecta because of safety concerns about it causing high levels of calcium in the blood. See https://clinicaltrials.gov/study/NCT02352753 I'm betting on $MREO (with $RARE, its partner on this drug) will own treatment for this indication with their Setrusumab (in Phase 3).
- woodman: $VKTX broke out last week, then sideways last few days. Now making a little flag. It is extended from the 50d and 200d with the 50 going to cross above the 200d soon. Shorter term, the 8dEMA has caught up again. It has oral and subq obesity drug cand ...
- joelsg1: @woodman $VKTX $LLY $AMGN $PFE You are kinda the expert around here :)
- woodman: @joelsg1 $VKTX $LLY $AMGN $PFE https://i.gifer.com/1VF5.gif
- joelsg1: @woodman $VKTX $LLY $AMGN $PFE More hair than I'd imagine.
- woodman: @joelsg1 $VKTX $LLY $AMGN $PFE - Am I not using my nose-hair scissors (that I told @bigbartabs about) enough?
- joelsg1: @woodman $GPCR Yep, still in this one. Hanging in despite lots of competition coming, particularly from a legacy holding $AMGN which I think is sandbagging their results in both injectable/pill forms.
- woodman: @joelsg1 $GPCR $AMGN - Also, $VKTX should have data for both oral and subq possibly as early as this Q for at least one of those, though I'd expect at least by 2Q for both.
- Onthemark: @pebbles $LLY $AMGN is making a nice cup and handle formation. $ISRG is breaking out today.
- pebbles: @Onthemark $LLY $AMGN $ISRG Thanks! I’ll start tracking.
- Henry: $AMGN Breaking out on a weekly chart
- joelsg1: @Henry $AMGN Legacy Lt holding for me since $47 and currently paying 3% divi. I've sold and rolled upside covered calls along the way to juice the return. I post alot of st momo trades here, which have worked very well in a rising market, but it's really hard to make large profits moving in and out even if you time them right. Better to do as Buffett does, buy great companies at fair prices and hold and if you must trade around the core pos., which I do.
- joelsg1: @woodman $GPCR $VKTX $XFOR $INZY $PDSB I wait with bated breath. Followed you into $VKTX for as I recall mixed results, but definitely think a pill is better than the injection, and duct tape across the mouth better yet. Btw, own $AMGN which has its own injectable but lasts at least 3 months per injection vs weekly for the others. Cheers.
- woodman: @joelsg1 $GPCR $VKTX $XFOR $INZY $PDSB $AMGN - Is Amgen's still phase 1?
- joelsg1: @woodman $GPCR $VKTX $XFOR $INZY $PDSB $AMGN In Phase 2 now.
- woodman: @joelsg1 $GPCR $VKTX $XFOR $INZY $PDSB $AMGN - That's good.
- joelsg1: $AMGN Breakout. Leerink to $318. Posted often, legacy holding since $47 with now lower yield divi, and they have their own weight loss drug among many others.
- oldtimer: using @Dan simple formula on TC2000 of above the 200ma, above the 50ma above the 21ma and above the 8ma in the Nasdaq 100 there are three stocks . .$ATVI, $AMGN, $SGEN per my screen. the DOW has one $AMGN, S&P has 16. $PKG, $WDC,$AIZ, $CF, $CBOE, $MOH, $MCK, $TXT, $WRK, $HAL, $ACGL, $XOM, $PSX, $ATVI, $AMGN, $REGN Slim Pickings
- Momentariness: @scottrades I looked through 600 charts and found 4 still breathing $AKAM, $AMGN, BJ, and TEVA
- scottrades: @Momentariness $AKAM $AMGN I've been following AKAM, nice breakout yesterday, lower open today. Would be interesting to see it hold up during this market volatility.
- joelsg1: $AMGN HOD-L.
- debeers: Might be a good time for discipline to triumph over wishin' and hopin' Have 8 stocks but all but 1 (my ittty bitty) all above the 21 day most at the 8 or above-$FDX above after earnings whic is up 12.50 $AMGN/ $ARDX/$AZO/$CEIX/$FDX/$LULU/$TXT/$X
- joelsg1: $NVDA $AMGN Both have large private equity-like investment funds which will power future growth, example Generate Biomedicines using AI for drug development now which will reduce trial costs and payoff later. Long both public companies. https://generatebiomedicines.com/news/series-c-financing-announcement
- woodman: @joelsg1 $NVDA $AMGN - Interesting, thanks. One I watch in the biotech/AI area, which seems to be involved in similar areas, is $QSI (np currently). https://ir.quantum-si.com/news-releases/news-release-details/quantum-si-and-biovista-partner-provide-ai-driven-deep#:~:text=This%20partnership%20combines%20Quantum%2DSi's,efficient%20protein%20drug%20target%20discovery. (As for $NVDA, I continue to hold it long term.)
- BarryC: Here are some things on my Watchlist BUT STILL in NO Rush.... $AMGN, $CLS, $CPE, $CVE, $CVNA, $EDU, $FRSH, $IP, $MNDY, $NVS, $TDW, $TUP, $WEAV, $YETI
- joelsg1: $AMGN Blasted up through 200d from E $30 in 3 days, nice balance to tech portfolio, $HZNP thyroid eye drug sales up 10% sequentially and on track acquisition this year, and they have an anti-obesity/diabetes/heart drug too, plus 9 others growing 10% plus. Long.
- joelsg1: $AMGN Strong E and move above 200d, Long.
- scottrades: Lots of Earnings to be aware of after the close: $AAPL $AMZN $COIN $FTNT $SQ $ABNB $DKNG $NET $OPEN $AMGN $TEAM $CRSR $MP $LTHM $FND $MCHP and more.
- joelsg1: $AMGN FTC weakness in $MSFT/$ATVI deal bodes well for $HZNP acquisition. Rolled up/out all short covered calls.
- joelsg1: $AMGN The FTC has filed its long awaited lawsuit to block the $HZNP deal, but waited until the last minute to do so. This to me is a positive. David Faber reported some settlement talks have occurred, thus waiting until the proverbial last minute to file indicates progress. The stock has marked a Head & Shoulders bottom which to me confirms around $250 on the weekly. Long.
- scottrades: Earnings after the close: $AMZN $INTC $SNAP $NET $FSLR $PINS $X $TMUS $GILD $AMGN $DXCM $SKX $COF $MDLZ $PFG $AYX $SAM $LHX $DLR $SWN $BJRI $AEM $SGEN $ACCD $FICO $IMAX $WY $RMD $ALSN $VRSN $KNSL $CINF $CAMP $CUBE $MHK $CC $CSL $APPF $SKYW $SLCA $HIG $SM $SNCY $ZYXI $OIS $COLM $GLPI $LPLA $AJG $BZH
- woodman: $AMGN news https://www.investors.com/news/technology/hznp-stock-rockets-as-amgen-agrees-to-buy-horizon-therapeutics/
- scottrades: $AMGN Flag
-
DrScience: @scottrades $AMGN Here's what I wrote yesterday on OMM about the stock...
$AMGN Let's take a look at the chart.... The stock is in a volatility squeeze with Price is below the 20 DMA. It's also below the 8 EMA, but above the 21 EMA. Price is stuck i ... - woodman: @DrScience $AMGN - Nice post, Doc. Also of note to me is that this squeeze is happening somewhat (fairly?) extended above the 50d. I think a breakout to the upside (if to the upside) would tend to have more power if starting closer to the 50d. But the Market doesn't care what I say or think. It often gives an unkind hand gesture and does the unexpected. Market gods have a cruel sense of humor.
- DrScience: @woodman $AMGN Hand gesture. Not just to the bears, but to the bulls, and anyone else that just happens to be looking. 🤣
- joelsg1: @DrScience $AMGN LT, and I mean really LT holding for me, had sold upside covered calls against shares but took all those off with the buzz about anti obesity drug earlier this year. 2.7% divi and large cap. gains make this an easy hold.
- woodman: @DrScience $AMGN The Market is an equal opportunity soul and wallet crusher.
- scottrades: My notes: $SPY 390 Support $QQQ Support at the 50 Day $DIA Support at 334 $GDX Bumping against the 200 Day $XME Going sideways $SMH Good strength but ceiling overhead $IGV At the 50 Day $XLK Flag $TAN No real direction $XHB Above the 200 Day $IBB Support at the 21 EMA $BITO Some volume today $NFLX and chill with Harry and Megan? $CELH Mentioned in the COTD $DKS Coming out of a flag $CPRX Sideways $DE Testing the highs $LSCC Holding the 8EMA $NVDA Watch the 200 Day $ON Above the 8EMA but still a bit loose $AMD Support at 69 $KLAC Base $AMAT Holding the 200 Day $ACLS Near the highs $AMGN Flag
- issues: @scottrades $SPY $QQQ $DIA $GDX $XME $SMH $IGV $XLK $TAN $XHB $IBB $BITO $NFLX $CELH $DKS $CPRX $DE $LSCC $NVDA $ON $AMD $KLAC $AMAT $ACLS $AMGN Thank you Scotty but I have not yet received the video and I do like hearing it instead of seeing these figures. Please SEND it to me, ok?
- woodman: @debeers @vcondry @Rockstar $LLY $NVO $AMGN - article on the 3 companies' new era weight loss drugs - https://www.washingtonpost.com/business/new-weight-loss-drugs-work-but-whos-paying/2022/11/09/ccea6bca-603b-11ed-a131-e900e4a6336b_story.html
- joelsg1: @debeers $LLY Prefer $AMGN and in , they have an approved drug for safety Otezla which has same weight loss effect, and apparently causes beaucoup burping. 2/3 cheaper than $LLY, double+ the divi, and steeper upward channel on chart as this plays catchup.
- woodman: @joelsg1 $LLY $AMGN https://www.investors.com/news/technology/amgen-stock-jumps-after-narrowing-race-in-obesity-treatment-with-novo-lilly/
- joelsg1: @woodman $LLY $AMGN Otezla being prescribed now for off-label weight loss use.
- vcondry: @joelsg1 $LLY $AMGN alright you talked me into it...got a little bit of Amgen too.
-
Rockstar: ...
So what do we do now. I was long the semis ($ON and $NVDA) on Monday, as mentioned in my missive on that day, and sold my positions on Tuesday. In hindsight it would have been a nice hold through yesterday's numbers, but I did not want to hold ... - jwstich: @Rockstar and @DAN $SPY $DIA $QQQ $IWM $ON $NVDA $SMH $XLV $AMGN $MRK $VRTX $MCK $XLE $CVX $XOM $DVN $OXY $XLF $GS $MET $AFL Do you still plan on combining SMM and OMM in some fashion? If so, when might this happen? I would be very much interested at looking at the combination. BTW, nice note this am Rocky.
- DAN: @jwstich $SPY $DIA $QQQ $IWM $ON $NVDA $SMH $XLV $AMGN $MRK $VRTX $MCK $XLE $CVX $XOM $DVN $OXY $XLF $GS $MET $AFL We are just working on the pricing now. I'm hoping that we can even get it done in time for Black Friday...and if not, then early December. It's a priority...there are just some complexities that are under the hood. Sorry for the delay.
- joelsg1: $PANW $TSLA Traveling all week with zero to poor internet. Did manage yesterday to open posted $PANW calls and spreads working out today with $ZM collaboration with Zoomtopia today. $AMGN also working with focus on their weight loss drug. Dwarfed by continued drop in $TSLA down 30% since 10/1, Musk polarizing tweets alienating his customers and Twitter overhang continues with thought he may have to sell shares to fund his vanity project. But numbers continue to rise, 54.5k China exports in Oct. and a bit lower than projected 17.2k domestic sales with price drop to meet subsidy in effect just last week. They also had a “ recall” for power steering disruption fixed by Over the air software update, no competitor can do that. Talk of buyback increasing with $20B free cash will support shares eventually, sooner than later. When it turns, and it will, happen fast.
- woodman: @joelsg1 $PANW $TSLA $ZM $AMGN - What Musk is doing to satisfy his ego and vanity is a tragedy for his shareholders. So self-destructive. But what's he care? He's the richest guy on the planet and essentially untouchable. There's a name for the kind of money he has, but I can't post it here.
- vcondry: @woodman $PANW $TSLA $ZM $AMGN " F U MONEY " I couldn't imagine the kind of freedom that brings to basically not take sh*t from anyone...he's lucky his company is in America or he would be the next Jack Ma ... I think we see a rebound at the 200 day @Scottrades posted earlier
- joelsg1: @woodman $PANW $TSLA $ZM $AMGN That name is "less". But still confident patience will be rewarded, lonely position now.
- woodman: @joelsg1 $PANW $TSLA $ZM $AMGN - "less" - LOL. Not what I was thinking, but true nevertheless. I hope he'll show some maturity (at 51), restraint, and self-correct his ways. I'd like to buy TSLA at some point. He doesn't make it easy for me to want to be involved with his ventures.
-
Rockstar: ...
I am looking at the $DIA and $IWM for longs. The sectors are $XLB,$XLE,$XLF,$XLV and I am eyeing the $SMH as well. I know that has more to do with the $QQQ's but that sector has shown some strength recently. The stocks I am looking at within thes ... -
Rockstar: ...
The $XLV is a sector I like as well with $MCK, $UNH,$VRTX,$AMGN and $LLY being my stocks to watch. Dan has had $LLY on the ATL and it is continuing its breakout. $VRTX reversed after earnings and is poised to make new highs. $UNH is pushing again ... - jpoko13: $AMGN break out gap and run
- joelsg1: $AMGN Still climbing despite Barclay's downgrade, but Day 3 of move. Long.
- vcondry: @cdmdave $MRNA when did they start selling alcohol? $MRNA $LLY $AMGN long ;-D
- joelsg1: $AMGN Up on MS target raise to $279, they have similar obesity drug to $LLY. Longtime hold.
- joelsg1: $AMGN Buying back 1/23 $270 covered calls for a buck, sold them in July for $7.85.
- vcondry: @joelsg1 $AMGN thats a solid risk reward
- debeers: $AMGN-positive lung cancer data according to Wells Fargo. winner stock
| Stock Price | $325.28 |
| Change | 1.05% |
| Volume | 1,978,130 |
Amgen Inc. is a biotechnology medicines company. It discovers, develops, manufactures and delivers innovative human therapeutics.
Request Video of AMGNAlready a member? Sign in here.
Past Month
Leading Peers
-
$46.62 377.44%
-
$16.44 68.83%
-
$6.70 66.08%
Past Month
Lagging Peers
-
$5.08 -40.84%
-
$21.31 -40.66%
-
$8.91 -37.08%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!